The MTPConnect $32 million Researcher Exchange and Development within Industry (REDI) program leverages the expertise of Australian research, training and industry partners to drive skills development and workforce training, through deployment of an integrated, three-pillar plan.
The Bridge and BridgeTech Industry Fellowship Program is part of pillar three: Industry Placements and Fellowships. The REDI initiative is funded through the Australian Government’s Medical Research Future Fund and will run from 2020-2024.
Bridge and BridgeTech Industry Fellowship Program partners
Along with MTPConnect and QUT, The Bridge Program and BridgeTech Programs involve support and input from a consortium of pharmaceutical and medtech companies, universities and industry associations:
- Bridge Program consortium includes: ACTI, ANU, UNSW, Roche, Yuhan, AbbVie, Amgen, Janssen, Macquarie University, Medicines Australia, MSD, Novartis and Pfizer
- BridgeTech Program consortium includes: Bosch, Cochlear, Stryker, Siemens, LSQ, ACTI, ANU, Flinders University, LSQ, Gadens, University of Melbourne, University of Newcastle, Magnetica, University of Western Australia and Vaxxas.
